ストックスクリーナーアプリを入手
26.10
0.46%
0.12
アフターアワーズ：
26.11
0.010
+0.04%
Dyne Therapeutics Inc (DYN) 最新ニュース
Royal Bank of Canada Buys 49,641 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits
Q3 EPS Forecast for Dyne Therapeutics Decreased by Analyst - MarketBeat
Handelsbanken Fonder AB Acquires Shares of 53,200 Dyne Therapeutics, Inc. $DYN - MarketBeat
Flputnam Investment Management Co. Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Aegis Wealth Management LLC Invests $3.33 Million in Dyne Therapeutics, Inc. $DYN - MarketBeat
Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells $54,012,900.00 in Stock - MarketBeat
Dyne therapeutics CFO Erick Lucera sells $47,225 in stock By Investing.com - Investing.com South Africa
Dyne Therapeutics CCO Executes Automatic Sale of 226 Shares to Cover RSU Tax Withholding - Kalkine Media
Dyne Therapeutics CEO John Cox Sells 4,986 Shares to Cover Tax Withholding on RSUs - Kalkine Media
Dyne therapeutics director Jason Rhodes sells $65.2m of common stock - Investing.com
Dyne Therapeutics (DYN) director's preset stock sale via Atlas funds - Stock Titan
Dyne therapeutics CFO Erick Lucera sells $47,225 in stock - Investing.com
Dyne Therapeutics (DYN) CFO sells shares in tax withholding trade - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) CCO sells shares to cover taxes - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) CMO has shares sold for tax withholding - Stock Titan
Dyne Therapeutics (DYN) CEO's tax-driven sale to cover RSU taxes - Stock Titan
Wainwright reiterates Dyne Therapeutics stock rating on trial outlook By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Bank of America Corp DE Has $26.17 Million Holdings in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics, Inc. SEC Filing (Aug 14, 2026) - Stock Titan
Dyne Therapeutics, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
DYN Company (Nasdaq: DYN) holder plans 4,986-share sale worth $131,034 - Stock Titan
DYN (DYN) insider notice details planned share sale and prior trades - Stock Titan
DYN (DYN) shareholder Doug Kerr plans sale of 2,443 common shares - Stock Titan
Dyne Therapeutics (DYN): Atlas Venture funds report 3.6% beneficial stake in 13G/A - Stock Titan
Dyne Therapeutics (DYN) gains 7.3% institutional holder Janus Henderson - Stock Titan
Dyne Therapeutics stock hits 52-week high at 27.19 USD By Investing.com - Investing.com Nigeria
Dyne Therapeutics stock hits 52-week high at 27.19 USD - Investing.com
Biotech Stocks At 52-Week HighsALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH - rttnews.com
The Bull Case For Dyne Therapeutics (DYN) Could Change Following FDA Clearance Of DYNE-302 Trial - webull.com
FMR LLC Expands Dyne Therapeutics Stake: A Strategic Bet on Neur - GuruFocus
Dyne Therapeutics (NASDAQ:DYN) Hits New 52-Week HighHere's What Happened - MarketBeat
Discipline and Rules-Based Execution in DYN Response - Stock Traders Daily
Dyne Therapeutics (DYN) Gets FDA Clearance With Valuation Questions Back In Focus - Sahm
Dimensional Fund Advisors LP Has $17.24 Million Holdings in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Inc (DYN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dyne Therapeutics, Inc. Revenue Breakdown – NASDAQ:DYN - TradingView
FMR LLC (DYN) discloses 6.8% Dyne Therapeutics stake in amended ownership filing - stocktitan.net
Dyne Therapeutics stock hits 52-week high at 26.8 USD By Investing.com - Investing.com UK
Dyne Therapeutics stock hits 52-week high at 26.8 USD - Investing.com
Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week HighShould You Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO) - The Globe and Mail
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Exploring a 56% Potential Upside for Biotech Investors - DirectorsTalk Interviews
Bank of New York Mellon Corp Buys 48,119 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Weekly Recap: BLA accepted for Z‑Rostudirsen and RBC raises PT to $35 - tradingview.com
Dyne Therapeutics, Inc. $DYN Shares Purchased by Renaissance Technologies LLC - MarketBeat
Dyne Therapeutics, Inc. $DYN Shares Purchased by Perceptive Advisors LLC - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Cut to Strong Sell at Wall Street Zen - MarketBeat
DYNE THERAPEUTICS, INC : RBC RAISES TARGET PRICE TO $35 FROM $30 - webull.com
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $45 - Moomoo
A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $44 to $47 - Moomoo
Dyne Therapeutics, Inc. $DYN Shares Sold by Vivo Capital LLC - MarketBeat
Janus Henderson Group PLC Sells 240,346 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
RBC Raises Price Target on Dyne Therapeutics to $35 From $30, Keeps Outperform, Speculative Risk - marketscreener.com
1.21%
1.07%
大文字化:
|
ボリューム (24 時間):